

REMARKS

Claims 41, 46, 51 and 63 are currently amended. Claims 47 and 59 are canceled. New claims 66-70 are presented. It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance. Reconsideration of the application in view of the above amendments and the following remarks is requested.

I: The Objections to Claims 47 and 59.

Claims 47 and 59 are canceled. Accordingly, any objection or rejection relating to these claims is moot.

II. The Rejection of Claims 41 and 46-49, 51, 52, 59-61, 63 and 64 under 35 U.S.C. 102(b).

Claims 41 and 46-49, 51, 52, 59-61, 63 and 64 were rejected under 35 U.S.C. 102(b) as being anticipated by Hartford and Dowds (Microbiology, 1994, Vol. 140, pp.297-304) (hereinafter referred to simply as "Hartford") as evidenced by (Mol. Micro., 1995).

Independent claims 41 and 46 are currently amended. Accordingly Applicants have been entirely responsive to the examiner. It is urged that Hartford does not show each and every element of the claimed invention. Reconsideration is urged.

III. The Rejection of Claims 41 and 46-65 under 35 U.S.C. 102(b).

Claims 41 and 46-65 were rejected as being anticipated by Chen et al. (1995, PNAS, Vol. 140, pp.297-304 ("Chen").

Independent claims 41 and 46 are currently amended. Accordingly Applicants have been entirely responsive to the examiner. It is urged that Chen does not show each and every element of the claimed invention. Reconsideration is urged.

III. New Claims

New claims 66-70 are presented. No new matter is added. Should any additional fees be due the USPTO is authorized to charge the deposit account of Novozymes North America, Inc, i.e., deposit account no. 50-1701.

IV. Conclusion

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to

contact the undersigned by telephone if there are any questions concerning this amendment or application.

Should any additional fees be due the USPTO is authorized to charge the deposit account of Novozymes North America, Inc, *i.e.*, deposit account no. 50-1701.

Respectfully submitted,

Date: January 28, 2011

/Michael W. Krenicky Reg#45411/
Michael W. Krenicky, Reg. No. 45,411
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097